Phase 2 N=20 Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Phase 2 N=36 A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
N/A N=20 Patient-Derived Organoids for Rectal Cancer
Rectum Cancer
Primary: Number of Participants With Biopsies That Form Spherical Organoids — 14 Participants
Phase 2 N=124 Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)
Medium and Lower Rectal Cancer
Primary: Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA — 1 Participants
Phase 2 N=27 Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
Colorectal Cancer
Primary: Pathologic Response and Complete Response — 3 Participants
Phase 2 N=66 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
N/A N=63 Non-Operative Management and Early Response Assessment in Rectal Cancer
Adenocarcinoma of the Lower Rectum
Primary: Clinical Complete Response Rate — 36; 2 Participants
Phase 3 N=225 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
Rectal Mucinous Adenocarcinoma · Rectal Signet Ring Cell Adenocarcinoma · Recurrent Rectal Carcinoma
Primary: 3-year Overall Survival Rate — 0.965; 0.843; 0.870 proportion of patients — p=0.35
Phase 2 N=135 Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants
Phase 2 N=321 Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer
Rectal Cancer
Primary: Number of Participants With Disease Recurrence — 53; 39 Participants — p=0.047
Phase 2 N=39 Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Colon Cancer · Rectal Cancer
Primary: Incidence of Complete Resection — 13 participants
Phase 2 N=83 S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 25 percentage of participants — p=0.18
Phase 2 N=139 Pre-op Rectal ChemoRad +/- Cetuximab
Rectal Cancer
Primary: Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval. — 26.6; 26.7 percentage of participants
N/A N=386 Efficacy of Segmental Examination Twice of the Proximal Colon on Adenoma Detection
Colonic Polyps
Primary: Difference of Adenoma Detection Rate in the Proximal Colon Among 2 Group. — 0.236; 0.331 proportion of participants
Phase 2 N=9 Chemoradiation or Brachytherapy for Rectal Cancer
Rectal Cancer
Primary: Number of Patients With Pathologic Complete Response — 0; 2 Participants
Phase 2 N=124 Tecemotide (L-BLP25) in Rectal Cancer
Rectal Cancer
Primary: Change From Baseline in Tumor Immune Response Evaluated by Immunohistochemical (IHC) Analysis of Tumor Infiltrating Lymphocytes (TILs) at Week 14 (Post-surgery) — 0.609…
Phase 2 N=146 Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 10.4; 20.8 percentage of participants
Phase 2 N=63 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
Anal Cancer
Primary: Local Failure Rate at 3 Years — 0.259; 0.353 proportion of participants — p=0.218
Phase 1 N=22 Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Rectal Cancer
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0 mg/m^2
Phase 2 N=58 NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Rectal Cancer
Primary: Percentage of Organ Preservation — 57 percentage of participants
N/A N=150 Ploidy and Stroma in Early Rectal Cancer
Rectal Cancer
Primary: Correlation Between Ploidy Status With Local Recurrence of Cancer — 3; 31; 14; 92 Participants
N/A N=14,263 Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
Colorectal Cancer · Advanced Adenocarcinoma · Serrated Polyp
Primary: ColoSense Sensitivity for Colorectal Cancer (CRC) — 25; 2 Participants
Phase 2 N=39 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
Rectal Cancer
Primary: Pathologic Complete Response Rate — 7 participants
Phase 2 N=25 Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Rectal Cancer
Primary: Pathologic Local Tumor Response — 8; 6; 11 Participants
Phase 2 N=46 Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Risk for Colorectal Cancer
Primary: Number of Participants With Anti Muc-1 Antibody — 39 participants
Phase 2 N=24 Phase II Study of Irinotecan and Panitumumab
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
N/A N=15 PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IIA Colon Cancer
Primary: Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the…